Skip to main content

Advertisement

Table 1 Characteristics and demographic data of patients with idiopathic inflammatory myopathies and healthy controls

From: The metastasis promoting protein S100A4 levels associate with disease activity rather than cancer development in patients with idiopathic inflammatory myopathies

  Dermatomyositis (DM) Polymyositis (PM) Cancer-associated myositis (CAM) Healthy controls (HC)
Number 43 39 22 77
Gender, female/male 35/8 25/14 20/2 58/19
Age, years 58 (41 to 63) 55 (36 to 60) 64 (59 to 70) 45 (31 to 54)
S100A4, ng/ml 26.7 (11.3 to 47.5) 41.6 (24.2 to 123.1) 28.8 (12.6 to 45.4) 23.8 (14.5 to 33.7)
S100A4, ng/ml in females 26.7 (9.0 to 54.7) 54.2 (25.4 to 115.6) 28.8 (13.0 to 47.5) 22.2 (13.6 to 32.1)
S100A4, ng/ml in males 30.3 (19.5 to 44.8) 41.3 (23.9 to 157.9) 20.3 (5.5 to 35.0) 32.3 (19.9 to 64.6)*
Disease duration, years 2.4 (0.4 to 8.3) 0.9 (0.5 to 3.2) 0.6 (0.2 to 3.6) NA
Biochemical markers     
CRP, mg/L 3.3 (1.3 to 9.0) 4.7 (2.2 to 26.1) 8.0 (3.2 to 26.6) NA
CK, ukat/L 2.6 (1.2 to 9.9) 11.6 (2.0 to 29.3) 10.9 (1.5 to 37.1) NA
LD, ukat/L 4.4 (3.5 to 6.4) 7.1 (4.2 to 10.9) 5.2 (2.9 to 6.0) NA
Autoantibodies 6*Mi-2 12*Jo-1; 11*TIF1 NA
4*TIF1, 1*TIF1 + U1RNP 1* Jo-1 + U1RNP; 4*Mi-2
2*NXP2 1*Jo-1 + RNAPI + RNAPII 2*Jo-1, 1*Jo-1 + Ro
3*PM-Scl 2*PM-Scl 1*SAE
3*Jo-1 1*PL7 3*without known aAbs
19*without known aAbs 1*Ku  
1*SRP
1*TIF1 + AMA
15*without known aAbs
Clinical features, number     
Muscle weakness 43 39 22 NA
Rash 42 1 16 NA
Mechanic's hands 18 10 8 NA
Raynaud's phenomenon 9 10 3 NA
Arthritis 14 14 4 NA
Interstitial lung disease 15 22 5 NA
Cardiac involvement 10 6 3 NA
Dysphagia 21 15 10 NA
Disease activity     
MYOACT 0.6 (0.15 to 1.5) 0.7 (0.2 to 1.3) 0.8 (0.5 to 1.8) NA
Constitutional DA, VAS 6 (0 to 18) 8 (0 to 24) 0 (0 to 28.5) NA
Cutaneous DA, VAS) 15 (0 to 30) 0 (0 to 6) 28.5 (0 to 52.8) NA
Skeletal DA, VAS 0 (0 to 0) 0 (0 to 7) 0 (0 to 2) NA
Gastrointestinal DA, VAS 0 (0 to 4) 0 (0to3) 0 (0 to 25.5) NA
Pulmonary DA, VAS 0 (0 to 7) 6.5 (0 to 24.7) 0 (0 to 13) NA
Cardiac DA, VAS 0 (0 to 0) 0 (0 to 0) 0 (0 to 0) NA
Extramuscular DA, VAS 15 (4 to 34) 17 (3.5 to 32.5) 20 (11.5 to 54.5) NA
Muscle DA, VAS 10 (3 to 44) 32 (14 to 53) 37 (5.5 to 68.3) NA
Physician's global disease Assessment, VAS 19.5 (4.5 to 43.7) 30.5 (22.5 to 49.3) 42.5 (13.5 to 52) NA
HAQ 1.0 (0.3 to 1.9) 0.9 (0.5 to 1.3) 1.0 (0.5 to 2.6) NA
MMT8 62 (52 to 74) 71 (63 to 74.5) 56 (50.5 to 69.0) NA
Treatment     
Treatment duration, months 13.6 (0.9 to 83.6) 2.0 (0.3 to 72.1) 1.4 (0.0 to 20.6) NA
Daily glucocorticoid dosage, mg prednisone equivalent 10.0 (2.5 to 40.0) 25.0 (3.8 to 50.0) 6.3 (0.0 to 42.5) NA
Immunosuppressive drugs 11*MTX, 3*Plaquenil, 2* AZA, 2*CyA, 23*no immunosuppressive drugs at the time of blood withdrawal, 2*before start of the immunosuppressive treatment 10*MTX,1*MTX + AZA, 1*MTX + SAS, 4*CyA, 2*Plaquenil, 1*AZA, 15*no immunosuppressive drugs at the time of blood withdrawal, 5*before start of the immunosuppressive treatment 4*MTX, 11*no immunosuppressive drugs at the time of blood withdrawal, 7*before start of the immunosuppressive treatment NA
  1. Data are presented as number or median (IQR). *S100A4 serum levels in males versus females, P = 0.025. NA, not applicable; CRP, C-reactive protein; CK, creatinine phosphokinase; LD, lactate dehydrogenase; aAbs, autoantibodies; MYOACT, myositis disease activity assessment; DA, disease activity; VAS, visual analogue scale; HAQ, health assessment questionnaire; MMT, manual muscle testing; MTX, methotrexate; AZA, azathioprine; CyA, cyclosporine A; SAS, sulfasalazine.